Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein  by Gordon, Larry M. et al.
Biochimica et Biophysica Acta 1778 (2008) 2127–2137
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemStructural and functional properties of peptides based on the N-terminus of HIV-1
gp41 and the C-terminus of the amyloid-beta protein
Larry M. Gordon a, Alex Nisthal b, Andy B. Lee c, Sepehr Eskandari b, Piotr Ruchala d,
Chun-Ling Jung d, Alan J. Waring a,d, Patrick W. Mobley c,⁎
a Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
b Department of Biological Sciences, California State Polytechnic University, Pomona, CA, USA
c Chemistry Department, California State Polytechnic University, Pomona, 3801 West Temple Avenue, Pomona CA 91768, USA
d Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USAAbbreviations: HIV-1, Human Immunodeﬁciency V
Immunodeﬁciency Virus, Type 2; gp41, glycoprotein 41,0
(23-residues) at the N-terminus of HIV-1 gp41 (LAV1a strain
virus; gp32, glycoprotein 32,000 of HIV-2/SIV; Aβ, amyloid-
42), amyloid-beta protein residues 1–40 or 1–42; Aβ(26–4
amyloid-beta protein; DLS, dynamic light scattering; TEM, tr
PIRA, parallel β-sheet, in register arrangement; PASTA, p
aggregation; PBS, phosphate-buffered saline, Phosphate bu
buffer, pH 7.4; HBS-EP buffer, 10 mM Hepes, pH 7.4, 150
surfactant P20;DMSO,dimethyl sulfoxide;HFIP, hexaﬂuorois
sulfate; TFE, triﬂuoroethanol; RBC, red blood cells; POPG,
dylglycerol; LUV, large unilamellar vesicles; POPC,1-palmito
POPG, 1-palmitoyl-2-oleoylphosphatidylglycerol; P/L, peptid
dichroism; FTIR, Fourier transform infrared; ATR, attenuated
dimensional Nuclear Magnetic Resonance; IR50, inhibitory r
tion to that themembrane-active agent that induces 50% inh
of the agent concentration to that the membrane-active age
ID50, inhibitor concentration that yields 50% inhibition for a
agent; PrP, prion protein; HPrP, human prion protein; B
molecular dynamics; SPR, surface plasmon resonance; CR, C
⁎ Corresponding author. Tel.: +1 909 869 3691; fax: +
E-mail address: pwmobley@csupomona.edu (P.W. M
0005-2736/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamem.2008.05.002a b s t r a c ta r t i c l e i n f oArticle history: Given their high alanine a
Received 1 November 2007
Received in revised form 7 April 2008
Accepted 6 May 2008











AIDSnd glycine levels, plaque formation, α-helix to β-sheet interconversion and
fusogenicity, FP (i.e., the N-terminal fusion peptide of HIV-1 gp41; 23 residues) and amyloids were proposed
as belonging to the same protein superfamily. Here, we further test whether FP may exhibit ‘amyloid-like’
characteristics, by contrasting its structural and functional properties with those of Aβ(26–42), a 17-residue
peptide from the C-terminus of the amyloid-beta protein responsible for Alzheimer's. FTIR spectroscopy,
electron microscopy, light scattering and predicted amyloid structure aggregation (PASTA) indicated that
aqueous FP and Aβ(26–42) formed similar networked β-sheet ﬁbrils, although the FP ﬁbril interactions were
weaker. FP and Aβ(26–42) both lysed and aggregated human erythrocytes, with the hemolysis-onsets
correlated with the conversion of α-helix to β-sheet for each peptide in liposomes. Congo red (CR), a marker
of amyloid plaques in situ, similarly inhibited either FP- or Aβ(26–42)-induced hemolysis, and surface
plasmon resonance indicated that this may be due to direct CR-peptide binding. These ﬁndings suggest that
membrane-bound β-sheets of FP may contribute to the cytopathicity of HIV in vivo through an amyloid-type
mechanism, and support the classiﬁcation of HIV-1 FP as an ‘amyloid homolog’ (or ‘amylog’).
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l rights reserved.1. IntroductionThe amino-terminal ‘fusion peptide’ (FP; residues 519–541; Fig. 1)
of glycoprotein 41,000 (gp41) is involved in the fusion processes
underlying human immunodeﬁciency virus (HIV-1) infection of target
cells [1,2]. Synthetic peptides based on the FP region induced leakage
of lipid vesicles [3], in agreement with the hypothesis that FP is
partially responsible for the cytolytic actions of HIV-1 virions.
Consistent with this is the ﬁnding that the FPs of HIV or SIV lysed
cultured cells [4–6] and erythrocytes [4,7–9]. FP addition to model
liposomes also induced lipid mixing and aggregation [3]. With red
cells, FP promotes not only rapid lipid mixing between cell
membranes, but also multicell aggregates [7,10,11]. Although these
results suggest that fusogenic actions of HIV-1 gp41 are mimicked by
FPs, an understanding of how this N-terminal domain produces lysis
and fusion has been complicated by its structural polymorphism.
Residue-speciﬁc spectroscopy have shown that FP residues ~1–4 to
15–20 (i.e., gp41 residues 519–537; Fig. 1) are conformationally
ﬂexible, folding as either an α-helix in membrane-mimics and
membranes [3,12–16], or oligomers of extended β-sheet in aqueous
and membrane lipid environments [3,14,17–20].
Fig. 1. Amino acid sequences of the native N-terminal peptide (FP) and the C-terminal
domain of the amyloid-beta protein [Aβ(26–42)]. FP is based on theHIV-1 strain LAV1a and
was numbered as described previously [7], while Aβ(26–42) is based on the C-terminal
region (residues 26–42) from the human amyloid β-peptide (residues 1–42) [42].
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of interest that the N-terminal gp41 peptide has been preliminarily
assigned to the same class of proteins as amyloids [21–23]. Using
sequence and hydrophobic analysis, Callebaut et al. [21] noted high
sequence homologies and elevated alanine and glycine levels in viral
fusion peptides such as HIV-1 FP and amyloid-derived peptides,
including the conserved hydrophobic sequences of human prion
protein (HPrP) responsible for peptide aggregation and neurotoxicity.
A recent study of the corresponding hydrophobic sequence from
bovine PrP (BPrP) also showed an interfacial hydrophobicity similar
to HIV-1 FP, indicating comparable membrane partitioning for these
peptides [23]. Additionally, suggestive of ‘amyloid-like’ properties
for the N-terminal gp41 domain is that aqueous FPs produce either
large spherical aggregates [14,24] or long ﬁlaments [14,23,25] that
bear analogies to ﬁbrils observed with the hydrophobic PrP peptides
[23,26]. Moreover, FTIR spectroscopy of the HIV-1 FP [14,23] or the
hydrophobic BPrP peptide [23] ﬁbrils demonstrated high β-sheet
levels. Another shared characteristic is polymorphism, as indicated
by CD or FTIR spectroscopic studies showing that the FP (see above)
and hydrophobic PrP peptides [23,26] may each adopt multiple
conformations. The lytic and fusogenic actions reported for HIV-1
FP (see above) and the neurotoxic PrP sequences [23,26] may be
due to these peptides converting between α-helix, β-sheet and
random coils [21]. Nevertheless, HIV-1 FP may not act as a classic
amyloid peptide, as solid-state 2D-NMR indicated that membrane-
associated FP simultaneously folds as parallel and antiparallel β-
sheets [27].
Because the assignment of HIV-1 FP as an ‘amyloid-like’ peptide
remains preliminary, it would be worthwhile to further compare
various structural and functional properties of this viral fusion peptide
with those of peptides based on the amyloid-beta protein (i.e., Aβ). Aβ
is a protein found in the extracellular deposits of Alzheimer plaques in
the brain. The naturally-occurring Aβ proteins in Alzheimer plaques
are approximately 39 to 43 residue peptides, with the 40-residue
Aβ(1–40) and 42-residue Aβ(1–42) variants being the most abundant
forms found in Alzheimer's disease. Aβ(1–42) is an amphipathic
protein, with a hydrophilic N-terminus region (1–28) and a hydro-
phobic C-terminal stalk (29–42) that anchors the protein in the
membrane bilayer [28]. 2D-NMR [29–31] and CD [32] analyses of
either the Aβ(1–40) or Aβ(1–42) proteins in membrane-mimics
indicated high α-helix, with 2D-NMR showing α-helix between
residues ~8–16 to 25 and ~28–31 to 35–38. The polymorphic nature of
Aβ is emphasized by prior CD and FTIR ﬁndings that this protein may
adopt β-sheet in either aqueous [33,34] or even membrane [32]
environments. Recent solid-state 2D-NMR spectroscopy indicated that
ﬁbrillar Aβ(1–40) primarily folds with a parallel β-sheet, in register
arrangement (PIRA) [35]. This is consistent with calculations using
PASTA (i.e., prediction of amyloid structure aggregation) analysis,
which systematically determines the relative energies of both parallel
and antiparallel β-sheet arrangements for the various pairings of a
protein, indicating that the most stable PIRA pairings for Aβ(1–40) areresidues 12–20 and 31–40 [36,37]. Intermolecular hydrogen-bonding
between Aβ molecules produces an ‘inﬁnitely long’ β-sheet with a
ﬁbril axis perpendicular to the extended Aβ chains. A second ﬁbril
axis, perpendicular to the plane of the β-sheet, is formed by
successively layering these β-sheets on top of one another [28]. Also
noteworthy are recent ﬁndings that full-length Aβ is neurotoxic [38],
and perturbs red blood cells [39,40].
Attention has focused lately on the critical roles that the hydro-
phobic C-terminal domain may play in the ﬁbril formation and
toxicity of the full-length Aβ protein. Based on separate approaches,
which calculate minimum energies for various sequence pairings
using the known 3D structures of proteins, Thompson et al. [41] and
Trovato et al. [36,37] each predicted that the full-length Aβ protein
would likely form PIRA alignments at the C-terminal region. It is of
considerable interest, then, that synthetic fragments based on the
Aβ sequence, which overlap the hydrophilic and hydrophobic
domains at the C-terminus, mimic the ﬁbrillar and cytotoxic actions
of the full-length protein (see above). The C-terminal fragments
Aβ(34–42) and Aβ(26–42) (Fig. 1) rapidly formed amyloid ﬁbrils in
aqueous buffers, and FTIR spectroscopy on each peptide ﬁbril
conﬁrmed high β-sheet levels [42–44]. More recently, the over-
lapping Aβ(25–35) in either aqueous media [45] or aqueous media
with liposomes [46] produced cross-beta ﬁbrils comparable to those
observed with the full-length Aβ protein [38]. C-terminal Aβ
peptides have also been found to be similarly lytic and fusogenic
with liposomes [47], and cytotoxic with neurons [6,48,49] and red
cells [40,50]. Consequently, the use of C-terminal Aβ peptides
provides a useful model system for probing key structural and
functional aspects of the parent protein.
To further assess the ‘amyloid-like’ characteristics of HIV-1 FP, we
here explore the properties of FP and Aβ(26–42) with a suite of assays,
several of which have not been previously used. The Nomenclature
Committee of the International Society of Amyloidosis has deﬁned
amyloids to include 25 human and 8 animal ﬁbril proteins, which are
all found as extracellular deposits in situ with amyloid characteristics
such as cross-β structure, afﬁnity for Congo red and cytotoxicity
[51,52]. Neither FP nor Aβ(26–42) would fulﬁll this strict amyloid
deﬁnition, because FP has not been observed as extracellular deposits
in AIDS patients, while Alzheimer plaque contains full-length Aβ
proteins. However, the Nomenclature Committee additionally deﬁned
‘amyloid homologs’, a related group of proteins or peptides that forms
ﬁbril aggregates only in vitro, but which nevertheless exhibit
‘amyloid-like’ properties [51–53]. Because C-terminal Aβ peptides
demonstrate typical ‘amyloid-like’ behaviors (see above), direct
comparisons between FP and Aβ(26–42) may show whether FP, like
Aβ(26–42), is also an ‘amyloid homolog’ or ‘amylog’ [53]. Both
peptides exhibit hydrophilic and hydrophobic regions, except that
their positions have been reversed (Fig. 1). To make these compar-
isons, we here employ standard techniques such as FTIR spectroscopy,
transmission electron microscopy (TEM) and hemolysis assays, and
also newer ones such as dynamic light scattering (DLS), PASTA, and
surface plasmon resonance (SPR) spectroscopy that have not been
used previously with FP. FTIR, TEM, DLS and PASTA analysis indicate
that aqueous FP and Aβ(26–42) each form β-sheet ﬁbrils, although the
FP ﬁbril interactions are weaker due to its core β-sheet being less
energetically favored. FP and Aβ(26–42) similarly lyse and aggregate
red cells, with FTIR indicating that the hemolysis-onsets correlate well
with the conformational shift of α-helix to β-sheet for each peptide in
model liposomes. Congo red (CR), a dye-marker of amyloid plaques in
vivo [51], inhibits either FP- or Aβ(26–42)-induced hemolysis at low
doses, and SPR shows that this may be due to high-afﬁnity CR-peptide
interactions. Taken together, our results support the classiﬁcation of
HIV-1 FP as an amyloid homolog, and suggest that FP bound to
membranes as β-sheets may contribute to the cytopathicity of HIV in
vivo (e.g., depletion of CD4+-lymphocytes) through amyloid-type
mechanisms.
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2.1. Materials
Peptide synthesis reagents, including FMOC amino acids and coupling solvents,
were obtained from AnaSpec (San Jose, CA) and Pharmco Products (Brookﬁeld, CT).
Congo red was purchased from Sigma Chemical Co. (St. Louis, MO). The HBS-EP buffer
was from Biacore (Uppsala, Sweden). All organic solvents used for sample synthesis
were HPLC grade or better.
2.2. Solid-phase peptide synthesis, puriﬁcation and characterization
The synthetic peptides used here (i.e., HIV-1 FP and Aβ(26–42); Fig. 1) were
prepared with either an Applied Biosystems (Foster City, CA) 431A solid-phase peptide
synthesizer or a Protein Technologies Symphony/Multiplex SPPS (Tucson, AZ)
synthesizer using an FMOC strategy [4,10,54,55] (double-coupling 2×45 min). The
peptides were cleaved using modiﬁed Reagent K (88.9% triﬂuoroacetic acid (TFA), 4.4%
Triisopropyl silane (TIS), 2.2% thioanisol and 4.4% water), precipitated by addition of ice-
cold diethyl ether and then collected by centrifugation. The peptides were puriﬁed with
reverse-phase HPLC techniques [14]. The predicted molecular masses for each peptide
were obtained by MALDI-TOF mass spectrometry using an ABI Voyager RP-RBT2
reﬂection time-of-ﬂight mass spectrometer (Applied Biosystems, Foster City, CA).
2.3. Preparation of human red blood cells (RBCs)
Human RBCs were prepared using outdated units from the local blood bank [8,55].
Besides the blood type and Rh factor, each unit of blood is thoroughly tested for
infectious diseases, including HIV-1 HIV-2, HTLV-1, syphilis, and hepatitis B and C. Red
cells were washed three times in 0.85% NaCl, and packed cells from the last wash were
suspended in isotonic phosphate-buffered saline (PBS) buffer, consisting of 120 mM
NaCl–2.7 mM KCl–10 mM Na2HPO4 (pH 7.4).
2.4. Hemolysis of human RBCs
To determine peptide-induced lysis, 10 μl of packed, washed cells was added to
0.5 ml of the isotonic PBS buffer, and then small aliquots (≤30 μl) of concentrated FP and
Aβ(26–42) (Fig. 1) in 0.1% acetic acid were added. After 30 min at 37 °C (unless
otherwise indicated), the suspensionwas centrifuged at approx. 5000 ×g for 1.5min and
the supernatant analyzed spectrophotometrically for hemoglobin at 540 nm [4].
Percent lysis was calculated using a reference of the average of two tubes inwhich 10 μl
of packed cells was incubated in 2% TX-100 in distilled water (0.5 ml) for 30min at 37 °C.
2.5. Coulter counter sizing of human RBCs
Aggregation of red cells at ﬁxed peptide concentrations was determined with
Coulter counter sizing [7,8,10,11]. Aliquots (10 μl) of washed, packed erythrocytes were
incubated in 0.5 ml of PBS with the indicated peptide at 37 °C for 30 min. Peptides were
added as described above for hemolysis assays. At the end of the incubation, an aliquot
of the reaction mixture was diluted 1/500 in isotonic PBS in a 20-ml disposable blood
vial (Baxter Diagnostics, Irvine, CA). Particle numbers in each of 6 size ranges were
determined with a Coulter Counter-Model ZF-1 (Coulter Electronics, Hialeah, FL). The
total particle volume (VT) was calculated as the summation over each of the 6 channels
of the number (NC) of particles in each channel multiplied by the maximum particle
volume (VMC) in each channel. Percent total volume in each channel (%TVC) is then
deﬁned as:
kTVC = 100 NC  VMCð Þ=VT½ : ð1Þ
2.6. Congo red (CR)-inhibition of FP- and Aβ(26–42) induced hemolysis of human RBCs
Determinations of Congo red (CR) inhibition of FP- or Aβ(26–42)-induced
erythrocyte lysis were performed with minor modiﬁcations of earlier protocols
[7,8,54,56]. First, aliquots (10 μl) of the packed cells were added to 0.5 ml of the
isotonic buffer, and then small aliquots (≤30 μl) of the concentrated CR (in 50% DMSO)
were added. For testing CR inhibition of FP- or Aβ(26–42)-induced RBC lysis, small
aliquots (≤30 μl) of the concentrated membrane-perturbing peptides (in 0.1% acetic
acid) were added to the mixture within 30 s after CR, and incubated for 30 min at 37 °C.
Hemolysis measurements were then performed as described above. Maximal hemolysis
(100%) was deﬁned as that obtained by incubating a high concentration (60 μM) of the
membrane-perturbing peptide [i.e., FP or Aβ(26–42)] with 10 μl of packed erythrocytes
in 0.5 ml of PBS for 30min, without CR inhibitor. Control experiments indicated that the
highest concentrations of carrier DMSO for CR inhibition or acetic acid for membrane-
perturbing peptides did not increase hemolysis.
2.7. Congo red (CR) binding to FP and Aβ(26–42) by Surface Plasmon Resonance (Biacore)
Binding afﬁnities of Congo red (CR) for FP and Aβ(26–42) were measured with a
Biacore 3000 system (Biacore, Uppsala, Sweden) [57]. FP and Aβ(26–42) were each
chemically linked to a CM5 sensor chip (BR-1000-14, research grade, containing a
carboxymethylated dextranmatrix covalently attached to a gold ﬁlm) through N-terminal
amine coupling. Solutions of CR in HBS-EP buffer (i.e., 10 mMHepes, pH 7.4,150mMNaCl,3 mM EDTA, 0.005% surfactant P20) were then ﬂowed over the chip-linked peptide at a
ﬂow rate of 50 μl/min to determine binding afﬁnity at 37 °C. Binding associated with
controlmedium containing noCRwas subtracted fromﬁnal afﬁnity curves, andmean “on”
and “off” rate constants (kon and koff) and the dissociation equilibrium constant (KD=koff /
kon) were calculated using BIAevaluation Software Version 4.1 based on curve ﬁtting from
measurements at 10 nM CR concentration. The sensor surface was regenerated using
10 mM HCl between each sample injection [58].
2.8. Dynamic light scattering (DLS)
DLS experiments were performed at 37 °C with a Dyna-Pro light scattering
instrument (Wyatt Technologies, Santa Barbara CA) for various times (0–40min), at 50%
laser intensity with a wavelength of 825.4 nm. The scattering angle was 90°. Scattering
measurements were obtained on solutions of 40 μM HIV-1 FP or Aβ(26–42) in
phosphate-buffered saline (PBS) pH 7.4, prepared by introducing small aliquots of
concentrated peptide stock solutions (5 mM) suspended in 0.1% acetic acid. Data was
sampled over 2 min, and analyzed by comparing the raw scattered light, and through
the use of an autocorrelation function and its ratio of decay employing Dynamics
Version 6.0 software. Particle translational diffusion coefﬁcients (DT) were determined
from autocorrelated light intensity data and converted to hydrodynamic radii (RH) with
the Stokes–Einstein equation. Histograms of percentage intensity vs. RH were
calculated, and intensity weighted mean RH were calculated for each subpeak [59].
2.9. Prediction of amyloid structure aggregation (PASTA) analyses
FP and Aβ(26–42) were each subjected to PASTA (i.e., prediction of amyloid
structure aggregation) analyses [36,37,60] to determine those peptide regions most
likely to aggregate as β-sheet. The PASTA algorithm systematically determines the
relative energies of the various pairing arrangements, by calculating a pair-wise energy
function for residues facing one another within a β-sheet. Using a database of known
3D-native structures, PASTA determines two different propensity sets depending on the
directionality (i.e., parallel or antiparallel β-sheets) of the neighboring strands. PASTA
assigns relative energies to speciﬁc β-pairings of two sequence stretches of the same
length, and assumes that lower relative energies promote aggregation by further
stabilizing the cross-β core.
Theoretical PASTA predictions of FP and Aβ(26–42) aggregation were performed
here by submitting the primary sequences of these peptides (Fig. 1) to the PASTA
website http://protein.cribi.unipd.it/pasta/ [36]. PASTA determines the relative energies
for the most stable pairings (i.e., parallel or antiparallel β-sheets), and outputs them to
the user as an HTML ﬁle (maximum pairings: 100). The assignment of the PASTA
energies for the top-ranked pairings allows the prediction of whether the β-sheet
domains of one peptide will be more stable than those of other peptides. The energies
for these pairings may also be used to compute an aggregation proﬁle of those regions
within a peptide most likely to aggregate as β-sheets. Here, the normalized aggregation
[i.e., h(k)] was determined as a function of amino acid position (k) of each peptide,
calculated using Eq. 5 of Trovato et al. [37] and outputted from the PASTA website as a
PDF ﬁle.
2.10. Attenuated Total Reﬂectance-Fourier transform infrared (ATR-FTIR) spectroscopy
Infrared spectra were recorded at 25 °C using Bruker Vector 22 FTIR spectrometers
(LA Biomedical Research Institute or California State Polytechnic University Pomona)
equipped with deuterated triglycine sulfate (DTGS) detectors, averaged over 256 scans
at a gain of 4 and a resolution of 2 cm−1 [3,10,14]. For FTIR spectra of FP or Aβ(26–42),
peptide self-ﬁlms were prepared by ﬁrst ﬁltering peptides suspended in 100%
hexaﬂuoroisopropanol (HFIP) with Whatman Nylon Syringe ﬁlters (0.2 μm pore size,
13 mm diameter; Fisher Scientiﬁc, Waltham, MA), and then air drying the ﬁltrates onto
50×20×2 mm 45° attenuated-total-reﬂectance (ATR) crystals ﬁtted for the Bruker
spectrometers (Pike Technologies, Madison, WI). The dried peptide self-ﬁlms were then
overlaid with solutions containing 100% HFIP or deuterated 10 mM sodium phosphate
buffer (pH 7.4) before spectral acquisition; control solvent samples were similarly
prepared, but without peptide. Spectra of peptides in solvent were obtained by
subtraction of the solvent spectrum from that of the peptide-solvent.
For measurements with FP or Aβ(26–42) in a lipid environment, large unilamellar
liposomes (LUV) of POPC:POPG (1mole:1mole) lipids in 10mM sodium phosphate buffer
(pH7.4) (500 nmol lipid/ml) of approx.100 nmdiameterwere prepared by freeze-thawing
ﬁve times, followed by ﬁvefold extrusion through polycarbonate ﬁlters using a LipoFast
apparatus (Avestin, Ottawa, CA) [10,61]. Peptides were added to the liposomes from 100%
HFIP, and allowed to incubate with the liposomes for 1 h. FTIR spectra were measured on
the above unchromatographedpeptide:liposomemixtures, and alsoon these peptide:lipid
samples passed through a Sephadex G-50 column to remove non-liposome associated
peptide [62]. Chromatographed and unchromatographed lipid–peptide samples were
dried onto theATR crystal. POPC:POPG lipid–peptide samples, and also control POPC:POPG
lipid samples without peptide, were hydrated for 2 h with nitrogen–D2O vapor, before
spectral measurement [3,10]. The peptide in POPC:POPG lipid spectrumwas obtained by
subtracting the POPC:POPG lipid with D2O hydration spectrum from that of peptide in
POPC:POPGwith D2O hydration. Peptide/lipid (P/L) ratios were determined here using the
earlierﬁndingofMartinet al. [62] that thepeptide concentration isproportional to the area
(Samide) of the amide I band (1680–1600 cm−1), while the lipid concentration is
proportional to the area (Sν(C=O)lipid) of the lipid ν(CfO) band (1770–1700 cm−1). Therefore,
the peptide/lipid ratio is proportional to the following ratio: (Samide) /(Sν(C=O)lipid).
Table 1
Proportions of secondary structurea for FP and Aβ(26–42) in HFIP and phosphate buffer,
as estimated from Fourier self-deconvolution of the FTIR spectrab of the peptide amide I
band
System % Conformation
α-Helix β-Sheet β-Turn Disordered
FP
HFIPc 54.8 8.3 29.9 7.0
Phosphate bufferd 20.1 40.4 19.5 20.0
Aβ(26–-42)
HFIPc 22.6 49.4 14.1 13.9
Phosphate bufferd 15.3 66.1 2.3 16.3
a Data are the means of four separate determinations and have an SE±5% or better.
b FTIR spectra were deconvoluted as described in Section 2.
c Peptide [i.e., 470 μM FP or Aβ(26–42)] dried on to an ATR plate from 100%
hexaﬂuoroisopropanol (HFIP) and resolvated with 100% HFIP (Fig. 2).
d Peptide [i.e, 470 μM FP or Aβ(26–42)] dried on to an ATR plate from 100% HFIP, then
resolvated with Phosphate buffer (i.e., deuterated 10 mM sodium phosphate buffer,
pH 7.4) (Fig. 2).
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secondary structures [3,14]. The proportions of α-helix, β-turn, β-sheet and disordered
conformations were determined by Fourier self-deconvolutions for band narrowing
and area calculations of component peaks using curve ﬁtting software supplied by
Galactic Software (GRAMS/32, version 5; Galactic Industries Corp., Salem, NH). The
frequency limits for the different structures were as follows: α-helix (1662 to 1645 cm
−1), β-sheet (1637 to 1613 and 1710 to 1682 cm−1), β-turns (1682 to 1662 cm−1) and
disordered or random (1650 to 1637 cm−1) [63].
2.11. Transmission electron microscopy (TEM)
HIV-1 fusion peptide (FP) and the Aβ(26–42) peptide in 0.1% acetic acid were each
diluted in PBS (pH 7.4) to a ﬁnal concentration of 40 μM and incubated at room
temperature directly on formvar-coated, carbon-stabilized 200-mesh copper grids (Ted
Pella; Redding, CA) for 1 h, 5 h, and 24 h [14]. At the end of incubation, the grids were
stained with 1% aqueous uranyl acetate for 5 min. Samples were then gently washed
ﬁve times with ultrapure water and allowed to dry. Control grids were treated in the
same manner with the exception of peptide inclusion in PBS. To enhance staining of
smaller structures, some samples were stained with 2% aqueous uranyl acetate for
10 min. Samples were examined in a Zeiss 10C transmission electron microscope at
80 kV. Images were collected on Kodak SO-163 ﬁlm at 25,000× to 50,000×. The electron
ﬁlms were digitized at 1200 dpi giving rise to a ﬁnal pixel size of 0.42 by 0.84 nm.
3. Results
3.1. FTIR spectroscopic analysis of FP and Aβ(26–42) in lipid-mimic and
aqueous environments
The secondary structures for FP and Aβ(26–42) in either the lipid-
mimic hexaﬂuoroisopropanol (HFIP) or phosphate-buffer environ-
ments were investigated using conventional 12C-FTIR spectroscopy.
Representative FTIR spectra of the amide I band for FP in the 100% HFIP
and 10 mM sodium phosphate-buffer (pH 7.4) systems are shown in
Fig. 2A. A principal band occurs at 1630 cm−1, and a minor high-ﬁeld
peak at ~1693 cm−1, for the phosphate-buffer spectrum (Fig. 2A).
Consistent with these ﬁndings, earlier FTIR spectroscopic studies of N-
terminal HIV-1 gp41 peptides (23-residues) in aqueous buffers each
demonstrated principal peaks in the range ~1620–1628 cm−1, and less
intense components at ~1689–1696 cm−1 [14,23,64]. It is likely that
the spectral features in Fig. 2A reﬂect interstrand β-sheets for FP in the
phosphate buffer [14,63,65]. On the other hand, FTIR spectra of FP in
the lipid-mimic HFIP solvent indicated a predominate band at
1657 cm−1 (Fig. 2A), and very similar spectra were previously reported
for FP in HFIP, POPG liposomes and SDS micelles [3,14]. Because priorFig. 2. Fourier transform infrared (FTIR) spectra of the amide I bands of FP (A) and
Aβ(26–42) (B) in either hexaﬂuoroisopropanol (HFIP) or aqueous environments.
(A) FTIR spectra of FP in 100% HFIP (solid line) or deuterated 10 mM sodium phosphate
buffer (pH 7.4) (dashed line). The amide I band for FP in HFIP shows a dominant α-
helical component centered at 1657 cm−1 (see arrow), while the corresponding band in
phosphate buffer indicates a major 1630 cm−1 (arrow) peak denoting β-sheet. (B) FTIR
spectra of Aβ(26–42) in 100% HFIP (solid line) or deuterated 10 mM sodium phosphate
buffer (pH 7.4) (dashed line). The amide I band for Aβ(26–42) in HFIP shows predominant
β-sheet (1628 cm−1 major peak, ~1693 cm−1 shoulder), and minor α-helix (1657 cm−1
secondary peak); the corresponding band in phosphate buffer indicates high β-sheet
(1626 cm−1 major peak, ~1693 cm−1 shoulder). Peptide concentrations were 470 μM, and
spectrawere recorded at room temperature. The abscissa (left to right) is 1740–1560 cm−1,
while the ordinate represents absorption (in arbitrary units).FTIR studies of proteins and peptides have assigned bands in the range
of 1650–1659 cm−1 as α-helical [63,65], FP in the HFIP solvent likely
assumes high α-helix levels. Fourier self-deconvolutions conﬁrmed
that FP is polymorphic, largely assuming α-helix (54.8%) in the lipid-
mimic HFIP while principally converting to β-sheet (40.4%) in phos-
phate buffer (Table 1). Because earlier circular dichroism (CD) spectra
of FP in aqueous buffer indicated unacceptably low signal/noise (e.g.,
Fig. 4B of Ref. [56]) due to low peptide solubility and high light
scattering, we here use ATR-FTIR spectroscopy that is not subject to
these limitations.
FTIR spectroscopy was also conducted to assess secondary struc-
tures of Aβ(26–42) in aqueous and HFIP environments. The FTIR
spectrum of Aβ(26–42) in phosphate buffer (pH 7.4) (Fig. 2B) indicates
a major peak at 1626 cm−1, and a minor peak at 1693 cm−1, consistent
with high amounts of extended β-sheet. Deconvolution of the aqueous
Aβ(26–42) spectrum in Fig. 2B conﬁrmed elevated levels of β-sheet
(66.1%), with much smaller amounts of α-helix (15.3%) and other
secondary structures (Table 1). Previous infrared spectroscopic results
with either the full-length Aβ protein or overlapping C-terminal
fragments are in agreement with these ﬁndings. For example, FTIR
spectra of Aβ(1–40) in aqueous buffer demonstrated elevated β-sheet,
as indicated bymajor (~1625 cm−1) andminor (~1685 cm−1) frequency
bands [34]. In an early infrared study of C-terminal Aβ fragments
dispersed inwater-free KBr, predominate β-sheet conformations were
identiﬁed from peaks at 1630 and 1695 cm−1 [66]. Moreover, aqueous
ﬁbrils of C-terminal Aβ peptides produced FTIR spectrawith dominant
maxima at ~1619–1630 cm−1 [42,43,46] and a high-ﬁeld shoulder at
~1690 cm−1 [43], similar to the corresponding spectrum of the over-
lapping C-terminal Aβ(26–42) in phosphate buffer (Fig. 2B).
To assess whether multiple conformations also occur with this
C-terminal Aβ peptide, FTIR spectroscopy was performed with
Aβ(26–42) in the lipid-mimic HFIP solvent. Fig. 2B shows the FTIR
spectrum of Aβ(26–42) in 100% HFIP, indicating both high β-sheet
(peaks at 1628 and 1693 cm−1) and low α-helix (secondary peak at
1657 cm−1). Spectral deconvolution veriﬁes that Aβ(26–42) in HFIP
largely retains a β-sheet conformation (49.4%), with small contributions
due to α-helix, β-turn and disordered structures (Table 1). Conse-
quently, Aβ(26–42) demonstrates only minor increases in α-helix (15.3
to 22.6%), and small decreases inβ-sheet (66.1 to 49.4%), as thepeptide is
moved from aqueous to the lipid-mimic HFIP. Because previous studies
of overlapping C-terminal Aβ peptides in membrane-mimics indicated
either β-sheets [33,46] orα-helix [67,68], the limited polymorphism for
Aβ(26–42) in the HFIP and aqueous environments (Fig. 2B) may reﬂect
this peptide forming more stable β-sheet adducts than those of FP
(see below).
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The peptide aggregates formed by FP and Aβ(26–42) in aqueous
phosphate-buffered saline (PBS; pH 7.4) were examined with
transmission electron microscopy (TEM). FP complexes are shown in
Fig. 3A for peptide incubated on the formvar-coated grid in PBS at room
temperature. For a 1-h incubation, the FP aggregates are a densemat of
networked ﬁbrils or ﬁlaments. Individual ﬁbrils are readily visualized
with diameters of 7–8 nm. Although the length of these ﬁbrils could
not be determined precisely due to the extensive networking, discrete
segments of loopy or curved ﬁlaments of 50–100 nm could be readily
traced. At the nexus of the ﬁbril branches are variably-sized aggregates
or bundles (~50–75 nm in diameter), which themselves consist of
smaller ﬁbrils (Fig. 3A). Similar networked ﬁbril aggregates (~75 nm in
diameter), aswell as spherical aggregates (~200 nm in diameter), were
also identiﬁed in an earlier TEM study of FP incubated in PBS (pH 7.4)
[14]. Comparable electron microscopic ﬁndings were made previously
on HIV-1 FPs, in which large ﬁbrillar bundles (~500–700 nm in
diameter) were identiﬁed in aqueous buffers [23–25], assembled from
long ﬁlaments ~5 nm in diameter [24].
Aβ(26–42) aggregationwas similarly studied here using TEM. For a
1-h incubation in PBS at room temperature, Aβ(26–42) forms a dense
mat of networked ﬁbrils (Fig. 3B). The individual ﬁbrils that constitute
this ﬁbrillar network exhibited diameters of 7–8 nm, and straight
ﬁbrils of 100 nm in length (or longer) could be readily identiﬁed. As
notedwith electronmicrographs of FP (Fig. 3A), however, the length of
the Aβ(26–42) ﬁbrils could not be accurately determined due to
considerable networking. At the intersections of the ﬁbril branches are
aggregates (50–100 nm in diameter), some of them nearly spherical,
and likely to be composed of smaller ﬁbrillar bundles (Fig. 3B). Earlier
electron microscopy of either Aβ(26–42) or overlapping C-terminal
Aβ peptides in aqueous buffer showed ﬁbril formation [42,43,46,66]
similar to that observed for Aβ(26–42) (Fig. 3B). Incubation of Aβ(1–
40) in aqueous media also demonstrated ﬁbrils (8 nm in diameter),
although these are typically ~500 nm or more in length [34], and thus
distinct from the shorter Aβ(26–42) ﬁbrils in Fig. 3B.
It is worthwhile to compare the respective ﬁbrils formed upon
incubation of FP and Aβ(26–42) in aqueous buffer. Electron micro-
scopy of either FP (Fig. 3A) or Aβ(26–42) (Fig. 3B) indicated networks
composed of constituent ﬁbrils (~7–8 nm), with dense aggregates
(~50–100 in diameter) at the branch intersections. The major
difference between the FP and Aβ(26–42) networks lies in the
connecting ﬁbrils, which are loopy (curved) ﬁbrils for FP (Fig. 3A)
but are much straighter for Aβ(26–42) (Fig. 3B). This morphologicalFig. 3. Transmission electron microscopy (TEM) of FP and Aβ(26–42) in phosphate-buffered
acid, and incubated at 37 °C for 1 h. (A) Image of uranyl acetate-stained grid in the presence o
PBS. Scale bar represents 100 nm.discrepancymay be due to the differences observed in the FTIR spectra
of FP and Aβ(26–42) in aqueous buffer. As noted in Fig. 2 and Table 1,
deconvolution of the FTIR spectra of aqueous FP indicated lower β-
sheet content, and higher levels of α-helix and β-turns, in comparison
to that determined for aqueous Aβ(26–42). Alternatively, the shift in
the absorption maximum for aqueous Aβ(26–42) in comparison to
that of aqueous FP (i.e., 1626 vs.1630 cm−1, respectively; Fig. 2) may be
a consequence of the β-sheet structure of Aβ(26–42) being somewhat
more extended and aggregated than that of FP [64,69]. Thus, stronger
β-sheet interactions may be responsible for aqueous Aβ(26–42)
exhibiting straighter ﬁbrils than those observed for aqueous FP
(Fig. 3). Such an interpretation would be consistent with the ﬁndings
from a joint electron microscopy and FTIR study that limited heat-
treated insulin (i.e., in aqueous buffer for 3 h at 70 °C) forms curved
ﬁbrils with high α-helix content and relatively low β-sheet [70].
Additional heat-treatment of insulin (i.e., in aqueous buffer for 48 h at
70 °C) converts these ‘young’ ﬁbrils into ‘mature’ ones more char-
acteristic of amyloid ﬁbrils; these mature ﬁbrils are straighter on
electronmicroscopy, and exhibit FTIR spectrawith an enhancedβ-sheet
component shifted to lower frequencies [69–71].
3.3. DLS of FP and Aβ(26–42) in PBS buffer
A further assessment of the respective aggregation of HIV-1 FP and
Aβ(26–42) in aqueous environments (PBS) was made using dynamic
light scattering (DLS). Light scattering has been used to quantitate the
aggregation state of full-length Aβ proteins [59,72]. In our present
studies, FP or Aβ(26–42) was initially stored in 0.1% acetic acid to
minimize peptide aggregation [17]. Fig. 4 shows the hydrodynamic
radii (RH) for FP and Aβ(26–42) at 2 min, indicating similar
aggregation proﬁles for both peptides with peaks centered at 300
and 5000 nm. The FP and Aβ(26–42) aggregates detected in DLS may
be related to those in electron microscopy (Fig. 3A and B) by noting
that, for non-interacting rod diameters of 8 nm, our 300 and 5000 nm
peaks approximately correspond to lengths of 900 to 50000 nm. As
pointed out earlier [72], these lengths would be smaller if rod–rod
interactions were occurring, while the actual lengths would be larger
if the rods were ﬂexible. Even with these caveats, however, our DLS
results are consistent with the large ﬁbrillar networks observed in
TEM of HIV-1 FP and Aβ(26–42) in PBS (Fig. 3A and B). It should be
emphasized that the aggregate sizes for either FP or Aβ(26–42) from
DLS are larger than the much smaller ﬁbrils reported for the full-
length Aβ(1–40) protein. In earlier studies [72,73], light scattering of
Aβ(1–40) indicated RH values from 10 to 50 nm, with correspondingsaline (PBS), pH 7.4. Peptides were diluted with PBS to 40 μM from 5 mM in 0.1% acetic
f FP and PBS. (B) Image of uranyl acetate-stained grid in the presence of Aβ(26–42) and
Fig. 5. Propensity for β-sheet aggregation [i.e., h(k)] plots determined for FP (A) and
Aβ(26–42) (B) from PASTA analyses [36,37]. The h(k) values are plotted for each peptide
residue (k), and normalized so that the summation of all h(k)s for a peptide equals 1.0.
The sequence and numbering for FP and Aβ(26–42) are in Fig. 1.
Fig. 4. Dynamic light scattering (DLS) proﬁle of HIV-1 FP (top) and Aβ(26–42) (bottom)
in PBS, pH 7.4. Peptides were diluted with PBS to 40 μM from 5 mM in 0.1% acetic acid,
and size readings were taken using a Dyna-Pro light scattering instrument at 37 °C
every 10 s for 2 min. Estimates of hydrodynamic radii (RH) were determined using the
Dynamics Version 6.0 software (see Section 2).
Fig. 6. Effects of the HIV-1 FP (●) and Aβ(26–42) (▾) peptides on the isotonic hemolysis
of erythrocytes (see Fig. 1 for sequences). Red cells (1×1011 cells/l) were incubated with
peptide for 30 min at 37 °C. Percent hemolysis is determined as described in Section 2;
100% hemolysis is deﬁned by incubating 10 μl of packed cells in 2% Triton X-100 in
distilled water (0.5 ml) for 30 min at room temperature. Peptide:lipid ratios were
calculated assuming quantitative uptake of each peptide by the red cells [4,10].
Numbers in parentheses next to the FP and Aβ(26–42) curves indicate the peptide
concentrations (μM) used in the incubations. Results are reported as the mean of
duplicate measurements, and are representative of three independent measurements.
The estimated SD for each value is ±5–8%.
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that aremuch smaller than our ﬁbrils. However, the Aβ(1–40) samples
were subjected to centrifugation and size-exclusion chromatography
to exclude large aggregates that might obscure the detection of small
oligomers [72,73].
3.4. Prediction of amyloid structure aggregation (PASTA) analyses of FP
and Aβ(26–42)
To further investigate the networked β-sheet ﬁbrils identiﬁed
above, energy calculations using PASTA analysis [36,37] were
performed on both FP and Aβ(26–42). PASTA indicated that FP will
most likely form a parallel β-sheet, in register arrangement (PIRA) for
residues 2–11 with a relative energy of −3.47. Using as a benchmark a
database of 179 peptides derived from the literature [36], a PASTA
energy threshold of −3.47 indicates that the probability that FP is
amyloid-like is ~72% (true positive rate). An aggregation proﬁle was
constructed for FP (Fig. 5A) (see Section 2), and also showed that the
sequence 2–11 would likely form β-sheets. Experimental conﬁrma-
tion of β-sheet for FP residues ~1–16 has been earlier obtained in
residue-speciﬁc spectroscopy of N-terminal gp41 peptides in PBS
buffer [14], model liposomes [17,19,20], and RBC ghost membranes or
liposomes at high peptide loading [3].
PASTA calculations were next conducted on Aβ(26–42), and also
indicated that the ﬁbrils identiﬁed above for this C-terminal Aβ
peptide are probably due to parallel, in register (PIRA) β-sheets. The
most stable PIRA pairing was for sequence 31–41, and showed a very
low PASTA energy of −8.08 with a probability of ~100% (true positive
rate) that this sequence is amyloid-like. The aggregation proﬁle for
Aβ(26–42) in Fig. 5B also demonstrates that residues ~31–41will form
β-sheets. These ﬁndings agree with those of the original PASTA
analysis of the C-terminal region of the Aβ protein [36,37], and are
veriﬁed by earlier residue-speciﬁc spectroscopic results on either the
full-length Aβ protein or C-terminal Aβ peptides. For example, solid-
state NMR spectroscopy of Aβ(1–40) ﬁbrils reported that the C-
terminal residues 30–40 form PIRA arrangements [35], while 13C-FTIR
spectroscopy of Aβ(34–42) in self-ﬁlms indicated that the sequence
36–41 folds as β-sheet [44]. It is of particular interest that much lower
PASTA energies of interactions are observed for the top-ranked
Aβ(26–42) pairings than the corresponding FP ones. A stronger
cross-β structuremight explain the FTIR absorptionmaxima occurring
at lower frequencies for Aβ(26–42) than for FP in aqueous media(Fig. 2A and B), and also account for the aqueous Aβ(26–42) ﬁbrils
being straighter than those for FP on TEM (Fig. 3A and B).
3.5. Lytic and aggregating actions of FP and Aβ(26–42) on human
erythrocytes
The respective hemolytic actions of the synthetic peptides FP (gp41
residues 519–541) and Aβ(26–42) (Fig. 1) were studied with human
RBCs suspended in isotonic buffer at 37 °C for 30min. Fig. 6 shows that
Fig. 8. FTIR spectra of FP (A) and Aβ(26–42) (B) in POPC:POPG liposomes at the indicated
peptide/lipid (FP/L or Aβ(26–42)/L) ratios. FP and the Aβ(26–42) in a stock solution of
100% HFIP were added to LUV of POPC:POPG (1:1) lipids in 10 mM sodium phosphate
buffer (pH 7.4). Peptide:liposomes were chromatographed to remove non-lipid-
associatedpeptide, asdescribed inSection2. Spectrawere recordedonchromatographed
peptide:liposomes thatwere dried on the ATR and hydratedwith D2O for 2 h. The arrows
at 1658 cm−1 in A and B indicate the α-helix component, while the arrows at 1629 and
1630 cm−1 in A and those at 1629 and 1626 cm−1 in B denote the β-sheet component.
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between40and60μM.Priorbatchesof synthetic FPproducedcomparable
hemolysis with human red cells [4,7,8,10,11,54]. Lytic activity may be a
general property of HIV FP, as the fusion peptides from both HIV-1 gp41
and HIV-2/SIV gp32 have been reported to be hemolytic with human red
cells [9]. Fig. 6 further shows that Aβ(26–42) produces a similar dose–
response proﬁle to that of FP, with a slightly higher maximum hemolysis
of ~40%. Comparable to that shown herewith Aβ(26–42), high hemolysis
was observed for incubations of the overlapping C-terminal Aβ(25–35)
peptide with human red blood cells [40,50].
Because FP and Aβ(26–42) each induce similar hemolytic activities,
these peptides were next tested for aggregation of human red cells.
Coulter counter studies were performed on washed, packed red cells
incubated in isotonic PBS with 60 μM doses of FP or Aβ(26–42). Counts
were made for particles in channels ranging in maximum particle
volume (μ3) from32 to1024. Plots of the percentage of total volume, %TV,
vs. the maximum particle volume are shown in Fig. 7, where %TV is the
percent of red cell particle volume in a given channel relative to the total
volume of the particles in all channels (see Section 2). Control
experiments with erythrocytes incubated in PBS alone showed a well-
deﬁned maximum centered at the 64 μ3 channel, denoting single cells.
For incubationswith 60 μMFP, however, there was a large decline in the
64 μ3 channel representing single cells, and an increase in the occupancy
of larger channels (i.e., ≥256 μ3) due to aggregated cells (Fig. 7). These
results are consistent with previous Coulter counter and electron
microscopic analyses showing that FP promotes the formation of red
cell multimers [7,8,10,11], and also agree with earlier ﬁndings that N-
terminal gp41 peptides aggregate model liposomes [64]. Fig. 7
additionally shows that 60 μM Aβ(26–42) reduces the number of single
cells and increases the proportion of multimeric cells, although the
aggregation inducedbyAβ(26–42) is less than that of FP. The aggregation
activity of Aβ(26–42) with red cells reported here is in accord with prior
experiments indicating that the full-length Aβ protein mediated lipid
vesicle association with cells [74], and also that overlapping C-terminal
Aβ peptides promoted aggregation of model liposomes [46,47,75].
3.6. FTIR spectroscopic analysis of FP and Aβ(26–42) in model liposomes
It is also worthwhile to characterize the secondary structures of FP
and Aβ(26–42) in environments in LUV of POPC:POPG (1:1). Because
the zwitterionic POPC and the anionic POPG are comparable to lipids
found in surface membranes, this mixture should be a more accurate
mimic of the lipid bilayer than HFIP solutions. With POPC:POPG (1:1)Fig. 7. Coulter counter sizing of erythrocytes treated with HIV-1 FP and Aβ(26–42).
Erythrocytes were tested for aggregation by incubating 10 μl of packed red blood cells,
diluted to 0.5 ml in PS buffer, with the following agents at 37 °C for 30 min: 60 μM FP
(●); 60 μM Aβ(26–42) (▾); control PBS (■). At the end of each incubation, an aliquot of
the reaction mixture was diluted 1/500 in isotonic phosphate-buffered saline. The
number of particles in each size range (i.e., maximum particle volume μ3, x-axis) shown
was then measured with a Coulter counter. Percent (total volume) for the particles in
each channel (y-axis) is calculated as in Section 2. Results are reported as the mean of
duplicate determinations, and are representative of three independent experiments.at a low FP/L of 0.014, the FTIR spectrum of the amide I band indicated a
dominant helical component centered at 1658 cm−1 (Fig. 8A). Impor-
tantly, nearly identical FTIR spectra were previously reported at these
low FP/L in either POPC:POPG (1:1) [10] or erythrocyte ghost liposomes
[3]. Subsequent deconvolution of the FP in POPC:POPG (P/L=0.014)
spectrum (Fig. 8A) conﬁrmed a high proportion of α-helix and much
lower levels of β-sheet (Fig. 9A) for this low P/L, which is non-lytic in
hemolysis assays (Fig. 6). FTIR spectra are also shown for FP in POPC:
POPG liposomes recorded over peptide concentrations (Fig. 8A) that
match those used in hemolysis assays (Fig. 6), and spectral deconvolu-
tions reveal the relative proportions ofα-helix andβ-sheet as a function
of P/L (Fig. 9A). As the FP/L increases from low (0.014) to high (0.400)
high ratios, Fig. 8A and Fig. 9A demonstrate that a second spectral
component arises centered at 1629–1630 cm−1 due to β-sheet, while
concurrently the α-helical component at 1658 cm−1 becomes dimin-
ished. The predominate β-sheet component obtained here for FTIR
spectra of POPC:POPG liposomes at high loading (i.e., FP/L of 0.133 or
0.400) (Fig. 8A) is similar to those observed for human RBC ghost
liposomes at high loading (FP/L of 0.100) [3], again indicating that POPC:
POPG liposomes are useful for assessing peptide conformations in bio-
membranes. The most likely explanation of the spectral results in Fig. 8A
and Fig. 9A is that raising the peptide level converts lipid-associated FP
fromα-helix at low loading toβ-sheet at high loading. It is also interesting
that the FP/L ratios that induce hemolysis (Fig. 6) are closely correlated
with the onset of signiﬁcant β-sheet (Fig. 8A and Fig. 9A), raising the
possibility that the lytic FP species is membrane-bound β-sheet.
FTIR spectra were also recorded with Aβ(26–42) added to POPC:
POPG liposomes at the same P/L ratios used to study hemolysis in Fig. 6.
For Aβ(26–42) in POPC:POPG (1:1) at a low P/L ratio of 0.014, the FTIR
spectrum in Fig. 8B indicated primarilyα-helix at 1658 cm−1, and lower
levels of β-sheet at 1629 cm−1. Spectral deconvolution of the Aβ(26–42)
spectrum (P/L=0.014) conﬁrmed that α-helix was the primary con-
formation at low loading, with smaller contributions due to β-sheet
(Fig. 9B). Similar to that noted for FP in Fig. 8A and Fig. 9A, increasing the
Aβ(26–42) concentration substantially elevated the proportion of the
β-sheet component, such that the β-sheet became the dominant con-
formation above P/L ratios of 0.014 (Fig. 8A and Fig. 9A). The Aβ(26–42)/
lipid ratios that induce hemolysis (Fig. 6) are correlated with the
Fig. 10. Congo red (CR) inhibition of hemolysis induced by FP (●) or Aβ(26–42) (▾).
Erythrocytes (1×1011 cells/l) were incubated with 60 μM FP or Aβ(26–42), and the
indicated concentrations CR for 30 min at 37 °C. Percent hemolysis was determined as
described in Section 2, and is reported as the mean of duplicate determinations. One
hundred percent maximal hemolysis for the inhibition curves is deﬁned as that
obtained by incubating 60 μM FP or 60 μM Aβ(26–42) with 10 μl of packed erythrocytes
in 0.5 ml of PBS, without inhibitor. The dashed horizontal line represents 50% of the
maximal hemolysis, observed without CR.
Fig. 9. Proportions of α-helix (●) and β-sheet (▾) for FP (A) and Aβ(26–42) (B) in POPC:
POPG (1:1) liposomes, at the indicated peptide/lipid ratios. The % secondary structure
conformationsweredetermined fromtheFTIR spectra of FP (Fig. 8A) orAβ(26–42) (Fig. 8B)
in lipid, as described in Section 2.
Table 2
Mean association and dissociation kinetic rate constants (kon, koff) and equilibrium
dissociation constants (KD), calculated from surface plasmon resonance (SPR)
measurements for aqueous Congo red (CR) ﬂowing past chip-linked FP and Aβ(26–42)
monolayers
Chip-linked peptide kon (1/Ms) koff (1/s) KD (nM)
FP 62.9×105 18.7×10−3 2.97
Aβ(26-42) 19.2×105 4.0×10−3 2.10
Congo red in HBS-EP buffer was ﬂowed past monolayers of FP or Aβ(26–42), linked via
their respective N-terminal amides to CM5 sensor chips in a Biacore 3000 system (see
Section 2). Mean kinetic rate constants (kon, koff) and equilibrium dissociation constants
(KD=koff /kon) were determined from curve ﬁtting analyses of SPR results at 10 nM CR.
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Aβ(26–42) like FP lyses RBCs by binding to membranes in a β-sheet
conformation.
3.7. Congo red (CR) inhibition of FP- and Aβ(26–42)-induced hemolysis
Because HIV-1 FP and Aβ (26–42) induce similar lytic activities
with human erythrocytes, FP and Aβ(26–42) may each be further
assessed for amyloid-like properties by testing the cross-inhibition of
their lytic activities by Congo red (CR). The actions of CR are
noteworthy, not only because this dye has been widely used as a
marker of amyloid deposits in situ [51,52,76], but also because it
reduces the cytotoxicity of various amyloids, including Aβ proteins
and peptides [38,40,77]. The concentration (60 μM) of membrane-
perturbing FP and Aβ(26–42) was chosen from hemolytic curves that
gave substantial release of hemoglobin (Fig. 6). For red cells
preincubated with a range of CR doses, inhibition plots were
constructed as the percent maximal hemolysis vs. the concentration
of CR (Fig. 10). Here, the percent maximal hemolysis for each
membrane-perturbing peptide [i.e., 60 μM FP or Aβ(26–42)] is deﬁned
as 100, without inhibitor (Fig. 6). The relative potency of CR in
reducing the membrane actions of FP and Aβ(26–42) may then be
determined from ID50s, calculated as those doses that produce 50%
inhibition for 60 μM FP or Aβ(26–42). For comparisons with archival
inhibition of HIV-1 FP- or Aβ peptide-induced toxicity, Congo red IR100
values were also calculated as the ratios of the CR concentration
to that of the membrane-perturbing peptide that produce 100%
inhibition.
The inhibition proﬁles of CR on FP- and Aβ(26–42)-induced
hemolysis are shown in Fig. 10. CR is an effective inhibitor of 60 μM
Aβ(26–42)-induced hemolysis, yielding an ID50 of 4.2 μM; at a higher
dose of 20 μM, CR completely blocked Aβ(26–42)-induced hemolysis,
with an IR100 of 0.33. These results are in good agreement withprevious studies of the human RBC lysis caused by either the over-
lapping Aβ(25–35) peptide or full-length Aβ(1–42), in which pre-
treatment with CR achieved IR100 values of ~0.2 [40]. It is of particular
interest that CR also lowered FP-induced hemolysis with ID50 (4.2 μM)
and IR100 (0.33) values identical to those seenwith Aβ(26–42) (Fig.10).
Our ﬁnding of very similar CR-inhibition patterns for both FP and
Aβ(26–42), combined with prior results showing that CR likewise
blocks the toxic activity of classic amyloid proteins found as plaques
in situ [38,40,77], further supports the assignment of both FP and
Aβ(26–42) as ‘amyloid homologs’.
3.8. Surface plasmon resonance (SPR) detection of Congo red (CR) binding
to FP and Aβ(26–42)
Given the high activity for Congo red in reducing either FP- or
Aβ(26–42)-induced hemolysis, it is important to determine whether
this inhibition may be due to the direct binding of CR to these pep-
tides. Here, we use surface plasmon resonance (SPR) spectroscopy to
assess CR binding to either FP or Aβ(26–42). SPR is a surface-sensitive
methodology, in which the ligand is chemically-linked to a sensor
surface, and the solute is then ﬂowed past the ‘chipped’ molecule. The
binding of the solute to the immobilized ligand produces an eva-
nescent response, which is proportional to the bound mass. SPR
experiments have recently detected high-afﬁnity binding of CR to
amyloid proteins (e.g., PrP [58,78] and Aβ(1–42) [79]) or amyloid
homologs (e.g., the C-terminal Aβ(10–35) peptide [80]). In the present
studies, FP and Aβ(26–42) are each chemically-linked to chips at their
respective N-terminal amine groups, while the solute CR in buffer is
ﬂowed past the immobilized peptides. Molecular binding afﬁnities
(associations) between the soluble CR and chip-linked ﬁlms of FP or
Aβ(26–42) were measured at 37 °C using a Biacore apparatus [57].
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binding (association) afﬁnity for CR based on high uptake rate con-
stants (kon) and low dissociation rate constants (koff). The respective
equilibrium dissociation constants (KD=koff/kon) for either FP or
Aβ(26–42) binding to CR were similarly low in Table 2, indicating
that CR had high afﬁnity for both peptides (Table 2).
4. Discussion
The present structural and functional comparisons of HIV-1 FP and
a C-terminal Aβ(26–42) peptide further support the hypothesis that
the N-terminal peptide of HIV-1 gp41 exhibits ‘amyloid-like’ char-
acteristics. Although FP and Aβ(26–42) do not fulﬁll the currently-
accepted deﬁnition of ‘amyloid’ because neither is found in extra-
cellular plaque in situ, these peptides may nevertheless belong to a
related class of ‘amyloid homologs’ that was recently described by the
International Society of Amyloidosis [51–53]. As noted in the
Introduction and Fig. 1, FP and Aβ(26–42) each have elevated alanine
and glycine levels, which is typical of amyloid-related peptides [21].
Another shared property of amyloid-like peptides is structural
polymorphism [21], and here we show that FP and Aβ(26–42) exhibit
high α-helix at low peptide loading in liposomes (Figs. 8 and 9), while
converting to β-sheet for peptides in either liposomes at high loading
(Figs. 8 and 9) or aqueous buffer (Fig. 2; Table 1). Results from FTIR,
TEM and DLS experiments show that these peptides readily form
extensive cross-β networks in vitro (Figs. 2–4) that mimic those
formed by actual amyloid proteins in vivo. FP and Aβ(26–42) similarly
lysed and aggregated human RBCs (Figs. 6 and 7), sharing the toxic
and fusogenic properties that are hallmarks of amyloid proteins [21].
Congo red potently inhibited the hemolytic actions of FP and Aβ(26–
42) (Fig. 10), probably due to the dye binding to these peptides with
high afﬁnity (Table 2). Congo red has been widely used as a marker of
amyloid deposits in vivo [51,52,76], and also blocks the cytotoxic
activities of classically-deﬁned amyloid proteins [38,40,77]. Taken
together, our results support the classiﬁcation of both FP and Aβ(26–
42) as ‘amyloid-like’ or ‘amyloid homologs’ [51].
Despite the ﬁndings here indicating that both FP and Aβ(26–42)
form networked β-ﬁbrils in aqueous buffer, results from energy
predictions and FTIR and TEM experiments also show that the FP
ﬁbrils are more easily deformed due to weaker core β-sheet
interactions. PASTA calculations indicated that FP and Aβ(26–42)
will each form parallel β-sheet, in register arrangements (PIRA)
(Fig. 5A and B), but that the cross-β structure will be considerably
stronger for the Aβ(26–42) peptide (see Section 3.4). Weaker β-sheet
interactions in the FP ﬁbrils may account for the FTIR maxima of
aqueous FP occurring at higher frequencies than those observed for
aqueous Aβ(26–42) (i.e.,1630 vs.1626 cm−1; Fig. 2). As noted in Section
3.2, the FP ﬁbrils are more loopy (curved) than those of Aβ(26–42) in
TEM (Fig. 3), probably due to the β-sheet of FP being less extended and
aggregated than that of Aβ(26–42). Interestingly, a recent survey
indicated that native β-sheet proteins typically yield FTIR spectra with
maxima at 1630 cm−1 and higher frequencies,while the corresponding
spectra of amyloid ﬁbrils exhibit maxima at 1630 cm−1 and lower [69].
With this FTIR classiﬁcation scheme, wewould assign Aβ(26–42) as an
amyloid, while FP might exhibit characteristics between those of
amyloid and native β-sheet proteins. PASTA analysis also here
categorizes FP as an amyloid with somewhat less conﬁdence than
Aβ(26–42) (i.e., true positive rates of ~72 and ~100%, respectively),
due to the prediction of weaker cross-β interactions in FP ﬁbrils
(see Section 3.4).
Close correlations were noted here between the onset of hemol-
ysis induced by either FP or Aβ(26–42) (Fig. 6) and the conversion of
α-helix to β-sheet for each peptide in liposomes (Fig. 8 and Fig. 9).
Although both FP and the C-terminal Aβ peptides have been ex-
tensively investigated, there are no generally acceptedmodels for how
these peptides exert their respective fusogenic and lytic activities oncells and liposomes. Earlier work on HIV-1 fusion peptides (for review,
see [3]) or Aβ proteins and peptides [32,47,75,81,82] indicated
possible roles for the deep insertion of peptides into lipid bilayers,
oblique intercalation of α-helical peptides into the membrane bilayer,
membrane aggregation of peptides, formation of membrane-asso-
ciated peptide in β-conformations, peptide-mediated membrane
ﬂuidization, peptide induction of non-bilayer lipid, and/or creation
of peptide–membrane pores. In the present studies, the FP/L or
Aβ(26–42)/L ratios that induce hemolysis (Fig. 6) are correlated with
the development of substantial β-sheet for these peptides in
liposomes (Fig. 8 and Fig. 9), suggesting that each peptide lyses RBCs
by binding to membranes in a perturbing β-sheet conformation.
Earlier residue-speciﬁc 13C-labeled FTIR studies of RBC ghost mem-
branes or liposomes [3] are in agreement with the above assignment
of membrane-bound, β-sheet FP as the hemolytic species. For
example, FTIR spectra of 13C-labeled FP in ghost liposomes indicated
that FP residues Gly-5 through Ala-15 were α-helix at a low, non-lytic
FP/L ratio of 0.014, but instead folded as β-sheet at a higher, lytic P/L of
0.10 [3]. These FP β-sheet adducts may require a highly-conserved,
stereospeciﬁc structure to produce membrane perturbations. Prior
studies indicated that several synthetic FP analogs (i.e., FP2V/E with
Val→Glu at residue 2; FP11F/Y with Phe→Tyr at residue 11; FPCLP1
with FP truncated at residue 7) were non-hemolytic, despite each
analog converting from α-helix at a low P/L (=0.013) to β-sheet at a
high P/L (=0.100) when bound to liposomes [10]. Interestingly, our
results are largely supportive of a mechanism proposed earlier by
Sackett and Shai [19], based on 13C-FTIR spectroscopy and model
building, which posited that the N-terminal gp41 domain would
mediate its membrane actions by ﬁrst forming trimeric FP sequences
folded with parallel β-sheet, in register alignments (PIRA) for residues
~1–16. An analogousmodel was also forwarded to explain the fusogenic
properties of the full-length Aβ protein and Aβ peptides [19], and our
results indicating that membrane-bound, β-sheet Aβ(26–42) is hemo-
lytic (Fig. 6 and Fig. 9) are consistent with this hypothesis.
The observation that HIV-1 FP perturbs membranes through
‘amyloid-like’ mechanisms may aid our understanding for how this
N-terminal gp41 domain participates in both the HIV life-cycle and
AIDS pathogenesis. Considerable evidence has now conﬁrmed the
involvementof the FP region inHIV-1mediated cytolytic and fusogenic
processes. For example, site-directed mutagenesis indicated defective
gp41 fusion activity for various modiﬁcations in the N-terminal
domain [10]. Moreover, synthetic peptides based on the FP re-
gion promoted leakage of lipid vesicles [3], and also lysed erythrocytes
[4,7–9] and cultured cells, includingCD4+-lymphocytes [4–6]. Here,we
showed that the N-terminal gp41 peptidemay induce RBC lysis at high
FP/L ratios (e.g., ≥0.10) (Fig. 6) through the formation of membrane-
bound β-sheet FP, as was detected adding FP to either erythrocyte
ghost lipids [3] or ghost lipid mimics (Fig. 8A and Fig. 9A). Given that
the lipid composition of RBC membranes is similar to that of
lymphocyte plasma membranes [83,84], it is likely that the synthetic
FP-induced lysis of CD4+-lymphocytes noted in the above in vitro
studies may also be due to amyloidogenic perturbations involving
surface membrane-bound, β-sheet FP adducts. This raises the
possibility that the in vivo depletion of CD4+-lymphocytes that is a
hallmark of AIDS patients may be partially due to amyloid-like actions
on lymphocyte plasma membranes triggered by the N-terminal gp41
domain of HIV-1 virions. To the extent that FP shares amyloid prop-
erties, it is also tempting to speculate that anti-HIV agents that block
the membrane perturbations of FP may also reduce the cytotoxic
actions of amyloids and amyloid homologs.
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